lubiprostone has been researched along with Chronic Disease in 41 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (43.90) | 29.6817 |
| 2010's | 16 (39.02) | 24.3611 |
| 2020's | 7 (17.07) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, ST; Bashashati, M; Fichna, J; Majewski, M; Milad, M; Sarosiek, J; Tarasiuk, A; Wallner, G | 1 |
| Miner, PB | 1 |
| Chey, WD; Jou, J; Shah, ED; Stidham, RW; Suresh, S | 1 |
| Eguchi, T; Hashimura, H; Ikeoka, S; Matsuda, T; Matsumoto, M; Miura, T; Momose, K; Morisawa, T; Okada, A; Okamoto, N; Otsuka, T; Takagi, M; Yoshizaki, T | 1 |
| Amioka, S; Eguchi, T; Fujinami, M; Ikeoka, S; Inoue, K; Katayama, N; Matsuda, T; Matsumoto, M; Momose, K; Morisawa, T; Noda, M; Nonaka, T; Okada, A; Sako, T; Takagi, M; Yamaguchi, T; Yoshizaki, T | 1 |
| Asano, T; Kimura, T; Kiuchi, M; Nagazumi, A; Ohbayashi, H; Sato, Y | 1 |
| Kawakami, E; Kimura, M; Miyazaki, C; Nagamura, M; Ooba, N; Sato, T; Shimada, M; Takahashi, M; Takahashi, Y; Tokuyoshi, J; Ushida, M | 1 |
| Fukushima, S; Handa, O; Handa, Y; Matsumoto, H; Murao, T; Osawa, M; Shiotani, A; Umegaki, E; Yo, S | 1 |
| Morrow, T | 1 |
| Nakamura, T; Node, K; Sato, E; Takeshita, M; Tanaka, A | 1 |
| Müller-Lissner, S | 1 |
| Cremonini, F; Gras-Miralles, B | 1 |
| Caporaso, JG; Crowell, MD; DiBaise, JK; Ilhan, ZE; Kang, DW; Krajmalnik-Brown, R; Rideout, JR; Rittmann, BE | 1 |
| Luthin, DR; Thomas, RH | 1 |
| Fu, T; Gao, Y; Li, CX; Li, F; Liu, BH; Tong, WD; Wang, XF; Wu, JS; Zhang, AP | 1 |
| Alvarez, A; Bashashati, M; Gomez, Y; Hall, M; McCallum, RW; Sarosiek, I; Sarosiek, J; Shankar, N | 1 |
| Cash, BD; Chang, L; Sabesin, SM; Vitat, P | 1 |
| Ambizas, EM; Ginzburg, R | 2 |
| Fried, M; Pohl, D; Tutuian, R | 1 |
| Chey, WD; Saad, R | 1 |
| Chey, WD; Lacy, BE | 1 |
| Gale, JD | 1 |
| Barish, CF; Drossman, D; Johanson, JF; Ueno, R | 1 |
| Rao, SS; Singh, S | 1 |
| Ford, AC; Suares, NC | 1 |
| Johanson, JF; Lembo, AJ; Miner, PB; Parkman, HP; Rao, SS; Ueno, R | 1 |
| Liu, LW | 1 |
| Camilleri, M | 1 |
| Bleser, SD | 1 |
| Crowell, MD; DiBaise, JK; Harris, LA; Olden, KW | 1 |
| Chagan, L; Rivkin, A | 1 |
| Lacy, BE; Levy, LC | 1 |
| Johanson, JF; Ueno, R | 1 |
| Geenen, J; Johanson, JF; Morton, D; Ueno, R | 1 |
| Cash, BD; Chang, E; Talley, NJ; Wald, A | 1 |
| Baker, DE | 1 |
21 review(s) available for lubiprostone and Chronic Disease
| Article | Year |
|---|---|
Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Topics: Chronic Disease; Constipation; Gastrointestinal Agents; Guanylyl Cyclase C Agonists; Humans; Irritable Bowel Syndrome; Isoquinolines; Lubiprostone; Natriuretic Peptides; Peptides; Randomized Controlled Trials as Topic; Sulfonamides | 2020 |
Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments.
Topics: Alprostadil; Anthraquinones; Benzofurans; Bisacodyl; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Humans; Laxatives; Lubiprostone; Peptides; Polyethylene Glycols; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
A critical appraisal of lubiprostone in the treatment of chronic constipation in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Alprostadil; Analgesics, Opioid; Chronic Disease; Constipation; Female; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Parkinson Disease; Randomized Controlled Trials as Topic | 2013 |
Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Topics: Chronic Disease; Clinical Trials, Phase III as Topic; Constipation; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Peptides | 2015 |
Lubiprostone Is Effective in the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Constipation; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Male; Middle Aged; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Update on the management of adults with chronic idiopathic constipation.
Topics: Adult; Alprostadil; Chronic Disease; Constipation; Dietary Fiber; Female; Gastrointestinal Transit; Humans; Indoles; Laxatives; Life Style; Lubiprostone; Male; Serotonin Receptor Agonists | 2007 |
Clinical pharmacology of lubiprostone, a chloride channel activator in defecation disorders.
Topics: Adult; Alprostadil; Chloride Channels; Chronic Disease; Clinical Trials as Topic; Constipation; Female; Humans; Irritable Bowel Syndrome; Lubiprostone | 2008 |
Pharmacologic treatment of constipation: what is new?
Topics: Alprostadil; Animals; Chronic Disease; Constipation; Drug Therapy; Drugs, Investigational; Humans; Irritable Bowel Syndrome; Lubiprostone; Probiotics; Serotonin 5-HT4 Receptor Agonists | 2008 |
Lubiprostone: chronic constipation and irritable bowel syndrome with constipation.
Topics: Alprostadil; Chloride Channels; Chronic Disease; CLC-2 Chloride Channels; Constipation; Gastrointestinal Agents; Humans; Ion Channel Gating; Irritable Bowel Syndrome; Lubiprostone; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Topics: Alprostadil; Azabicyclo Compounds; Benzofurans; Chloride Channels; Chronic Disease; Constipation; Gastrointestinal Agents; Gastrointestinal Motility; Guanylate Cyclase; Humans; Indoles; Irritable Bowel Syndrome; Laxatives; Lubiprostone; Peptides; Safety; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists; Treatment Outcome | 2009 |
Pharmacologic management of chronic constipation.
Topics: Alprostadil; Chronic Disease; Colchicine; Constipation; Guanylate Cyclase; Humans; Laxatives; Lubiprostone; Motilin; Narcotic Antagonists; Neurotrophin 3; Prebiotics; Probiotics; Receptors, Enterotoxin; Receptors, Guanylate Cyclase-Coupled; Receptors, Peptide; Surface-Active Agents | 2010 |
Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis.
Topics: Alprostadil; Benzofurans; Chronic Disease; Constipation; Diarrhea; Humans; Laxatives; Lubiprostone; Peptides; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Chronic constipation: current treatment options.
Topics: Alprostadil; Benzofurans; Chloride Channels; Chronic Disease; Constipation; Feedback, Physiological; Gastrointestinal Motility; Humans; Laxatives; Life Style; Lubiprostone; Peptides | 2011 |
New treatment options for chronic constipation: mechanisms, efficacy and safety.
Topics: Alprostadil; Bile Acids and Salts; Chloride Channels; Chronic Disease; Constipation; Gastrointestinal Agents; Humans; Indoles; Lubiprostone; Organic Anion Transporters, Sodium-Dependent; Peptides; Receptors, Serotonin, 5-HT4; Serotonin 5-HT4 Receptor Agonists; Serotonin Agents; Symporters | 2011 |
Chronic constipation: let symptom type and severity direct treatment.
Topics: Alprostadil; Cathartics; Chronic Disease; Constipation; Dietary Fiber; Fatty Acids; Gastroenterology; Gastrointestinal Agents; Humans; Indoles; Lubiprostone; Referral and Consultation | 2006 |
Activation of type-2 chloride channels: a novel therapeutic target for the treatment of chronic constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chloride Channels; Chronic Disease; CLC-2 Chloride Channels; Constipation; Diarrhea; Fatty Acids; Humans; Lubiprostone; Models, Biological; Nausea; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Lubiprostone: chloride channel activator for chronic constipation.
Topics: Alprostadil; Animals; Chloride Channels; Chronic Disease; CLC-2 Chloride Channels; Clinical Trials as Topic; Constipation; Fatty Acids; Humans; Ion Channel Gating; Lubiprostone; Treatment Outcome | 2006 |
Lubiprostone: a chloride channel activator.
Topics: Alprostadil; Cathartics; Chloride Channels; Chlorides; Chronic Disease; Constipation; Fatty Acids; Female; Gastrointestinal Transit; Humans; Lubiprostone; Male | 2007 |
Lubiprostone: a chloride channel activator for treatment of chronic constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Fatty Acids; Humans; Lubiprostone | 2007 |
Managing the chronically constipated adult: emerging approaches to diagnosis and treatment.
Topics: Aged; Alprostadil; Cathartics; Chronic Disease; Constipation; Fatty Acids; Female; Humans; Lubiprostone; Male; Middle Aged | 2007 |
Lubiprostone: a new drug for the treatment of chronic idiopathic constipation.
Topics: Alprostadil; Animals; Chloride Channels; Chronic Disease; Constipation; Drug Evaluation; Fatty Acids; Humans; Lubiprostone; Treatment Outcome | 2007 |
4 trial(s) available for lubiprostone and Chronic Disease
| Article | Year |
|---|---|
Response to lubiprostone in chronic constipation is associated with increased mucus and mucin output: a randomized clinical trial.
Topics: Chloride Channel Agonists; Chronic Disease; Constipation; Defecation; Double-Blind Method; Gastric Mucins; Gastric Mucosa; Humans; Kansas; Lubiprostone; Mucus; Treatment Outcome | 2019 |
Efficacy and safety of lubiprostone in patients with chronic constipation.
Topics: Adult; Alprostadil; Chronic Disease; Constipation; Defecation; Double-Blind Method; Female; Follow-Up Studies; Humans; Laxatives; Lubiprostone; Male; Middle Aged; Treatment Outcome | 2010 |
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.
Topics: Adolescent; Adult; Aged; Alprostadil; Chloride Channels; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids; Female; Gastrointestinal Agents; Humans; Lubiprostone; Male; Middle Aged; Treatment Outcome | 2007 |
Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids; Female; Follow-Up Studies; Humans; Lubiprostone; Male; Middle Aged; Peristalsis; Severity of Illness Index; Treatment Outcome | 2008 |
16 other study(ies) available for lubiprostone and Chronic Disease
| Article | Year |
|---|---|
Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation.
Topics: Chronic Disease; Constipation; Female; Gastrointestinal Agents; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Medication Adherence; Michigan; Middle Aged; Peptides; Retrospective Studies | 2020 |
Risk Factors for Adverse Events in Patients with Chronic Constipation Following Lubiprostone Administration.
Topics: Aged; Chronic Disease; Constipation; Feces; Female; Humans; Logistic Models; Lubiprostone; Male; Multivariate Analysis; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Real-World Comparison of Elobixibat and Lubiprostone Treatment in Patients with Chronic Constipation: A Propensity Score-Matched Analysis.
Topics: Chronic Disease; Constipation; Defecation; Dipeptides; Female; Humans; Laxatives; Lubiprostone; Male; Middle Aged; Propensity Score; Retrospective Studies; Thiazepines; Treatment Outcome | 2021 |
Open-label study to evaluate the treatment continuation rate after a dose reduction of lubiprostone due to onset of adverse events.
Topics: Adult; Aged; Chloride Channel Agonists; Chronic Disease; Constipation; Diarrhea; Drug Tapering; Female; Humans; Lubiprostone; Male; Middle Aged; Nausea; Vomiting; Withholding Treatment | 2021 |
Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study.
Topics: Aged; Aged, 80 and over; Chloride Channel Agonists; Chronic Disease; Cohort Studies; Constipation; Dipeptides; Female; Gastrointestinal Agents; Humans; Japan; Lubiprostone; Male; Middle Aged; Retrospective Studies; Surveys and Questionnaires; Thiazepines | 2021 |
Evaluation of efficacy and safety of lubiprostone in patients with chronic constipation.
Topics: Aged; Chronic Disease; Constipation; Female; Humans; Lubiprostone; Male; Retrospective Studies | 2021 |
$850 Per Bowel Movement?! Hard To Justify That Cost.
Topics: Chloride Channel Agonists; Chronic Disease; Clinical Trials as Topic; Constipation; Drug Costs; Drug Prescriptions; Gastrointestinal Agents; Guanylyl Cyclase C Agonists; Humans; Laxatives; Lubiprostone; Natriuretic Peptides; Nonprescription Drugs; Peptides | 2017 |
Effect of Lubiprostone on Urinary Protein Excretion: A Report of Two IgA Nephropathy Patients with Chronic Constipation.
Topics: Adult; Chronic Disease; Constipation; Disease Progression; Fatty Acid-Binding Proteins; Female; Glomerulonephritis, IGA; Humans; Lubiprostone; Occult Blood; Proteinuria | 2019 |
Lubiprostone for chronic constipation in adults.
Topics: Adult; Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Drug Costs; Humans; Lubiprostone | 2014 |
Gut microbial and short-chain fatty acid profiles in adults with chronic constipation before and after treatment with lubiprostone.
Topics: Adult; Aged; Biodiversity; Case-Control Studies; Chloride Channel Agonists; Chronic Disease; Constipation; Fatty Acids, Volatile; Female; Gastrointestinal Microbiome; Gene Dosage; Humans; Lubiprostone; Male; Metagenome; Middle Aged; RNA, Ribosomal, 16S; Treatment Outcome | 2015 |
Lubiprostone Accelerates Intestinal Transit and Alleviates Small Intestinal Bacterial Overgrowth in Patients With Chronic Constipation.
Topics: Adult; Blind Loop Syndrome; Breath Tests; Chronic Disease; Constipation; Female; Gastrointestinal Agents; Gastrointestinal Transit; Humans; Intestine, Small; Lactulose; Lubiprostone; Middle Aged; Treatment Outcome; Young Adult | 2016 |
Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation.
Topics: Alprostadil; Chloride Channel Agonists; Chronic Disease; Constipation; Dose-Response Relationship, Drug; Humans; Irritable Bowel Syndrome; Lubiprostone | 2008 |
FDA approves one drug for irritable bowel syndrome but suspends another.
Topics: Alprostadil; Chronic Disease; Drug and Narcotic Control; Drug Approval; Gastrointestinal Agents; Humans; Indoles; Irritable Bowel Syndrome; Lubiprostone; United States; United States Food and Drug Administration | 2008 |
Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation.
Topics: Adult; Alprostadil; Cathartics; Chloride Channel Agonists; Chronic Disease; Constipation; Drug Administration Schedule; Female; History, 18th Century; Humans; Lubiprostone; Male; Middle Aged | 2011 |
Lubiprostone (amitiza) for chronic constipation.
Topics: Alprostadil; Chloride Channels; Chronic Disease; Clinical Trials as Topic; Constipation; Fatty Acids; Female; Gastrointestinal Agents; Humans; Lubiprostone; Pregnancy | 2006 |
Fresh perspectives in chronic constipation and other functional bowel disorders.
Topics: Adult; Alprostadil; Cathartics; Chloride Channels; Chronic Disease; Clinical Protocols; Constipation; Defecation; Fatty Acids; Humans; Irritable Bowel Syndrome; Lubiprostone; Male; Manometry; Patient Satisfaction; Treatment Outcome | 2007 |